5省市二线抗结核药品供应保障现状调研及政策建议  

Research on the Supply Situation of the Second-line Anti-Tuberculosis Drugs in 5 Provinces&Cities and Policy Suggestion

作　　者：刘昭 张国龙 高雨龙[4] 范景庆[4] 张帆 赵琨 刘跃华 LIU Zhao;ZHANG Guo-Long;GAO Yu-Long;FAN Jing-Qing;ZHANG Fan;ZHAO Kun;LIU Yue-Hua(Health Development Research Center of National Health Commission,Beijing 100191,China;National Comprehensive Evaluation Center of Drugs and Health Technology of National Health Commission,Beijing 100191,China;Center for Disease Control and Prevention of Henan Province,Zhengzhou 450047,China;Institute of Tuberculosis Control and Prevention of Inner Mongolia Autonomous Region,Hohhot 010070,China)

机构地区：[1]国家卫生健康委卫生发展研究中心,北京100191 [2]国家卫生健康委国家药物和卫生技术综合评估中心,北京100191 [3]河南省疾病预防控制中心,郑州450047 [4]内蒙古自治区结核病防治研究所,呼和浩特010070

出　　处：《中国药物经济学》2021年第2期121-124,共4页China Journal of Pharmaceutical Economics

基　　金：中国国家卫生健康委员会-盖茨基金会结核病防治合作项目(三期)(2019-102-03236)。

摘　　要：通过对中国5个省市地区二线抗结核药品的供应保障情况进行调研,对关键知情人进行焦点小组访谈,分析供应保障问题,为相关政策制定提供参考。调研发现,我国三级结核病防治网络建设基本完善,各地耐药患者疗程用药方案基本配齐。部分药品存在采购价格过低、采购量不足、供应效率低等问题。相关方存在缺乏国家层级政策统筹、医保实际报销水平较低、结核科边缘化等执行困难。建议针对性开展国家集中采购和定点生产;加速抗结核新药研发、引进;鼓励仿制药研发、上市,完善相关保障制度和监管体系,使更多耐药结核患者受益。This paper investigates the supply of second-line anti-tuberculosis drugs in 5 provinces and cities in China,conducts focus group interviews with key informants,analyzes supply issues,and provides reference for relevant policy formulation.The investigation finds that China has built perfect the 3-level tuberculosis control network,and the medication regimen for drug-resistant patients in various regions is basically complete.Some drugs have several problems such as low purchasing price,insufficient purchasing quantity,inefficient supply etc.Some implementation difficulties are as follows:lack of top-level design,insufficient actual reimbursement of medical insurance and marginalization of tuberculosis department.It is suggested that government should carry out centralized procurement and designated production,accelerating the R&G and importation of innovative anti-tuberculosis drugs,encouraging the R&G and listing of generic drugs,and improving the security and regulatory system,so as to benefit more drug-resistant tuberculosis patients.

关 键 词：二线抗结核药品 耐多药结核 可负担性 可及性 供应保障 

分 类 号：R978.3[医药卫生—药品] R956[医药卫生—药学]